You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company is developing a methylated DNA biomarker that will predict all-cause mortality risk and risk of developing certain age-related diseases.
Within the country's first whole-genome sequencing program, researchers hope to initially focus on identifying markers associated with hereditary diseases and cancer risk.
The team compiled these proteins in three panels that could help researchers better assess plasma sample quality in protein biomarker work.
Biocept will offer patient data from its liquid biopsy tests to Prognos, who will apply artificial intelligence to ensure that patients receive correct therapies.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
The company said it will use the award to further develop its ImmuneProfiler neoantigen prediction technology for personalized cancer medicine.
The company, which went public in 2017, generates all its revenues through its epigenetic biomarker research and development partnerships.
Janssen R&D will use BiomX's microbiome-based biomarker discovery platform to identify IBD patients likely to respond to a particular therapy.
Researchers have shown nanoparticles can enrich low molecular weight, low abundance plasma proteins that are hard to detect using standard proteomic workflows.
The company said its test is the first biomarker-based diagnostic for IBD that predicts long-term disease outcome in Crohn's disease and ulcerative colitis.
The researchers will combine genomic analysis with environmental and mobile device data from 1,200 participants to try to better understand the disease.
OMI researchers will apply and validate 1CellBio's inDrop system to generate predictive data for patients with undiagnosed immune dysfunction conditions.
Oxford BioDynamics will work with Italian research institute Casa Sollievo della Sofferenza to identify blood-based biomarkers of autism spectrum disorder.
Researchers found that combining tumor and cancer cell line data with their MAGNETIC analysis approach could enhance drug response predictions.
The firms have agreed to conduct joint research using NanoString's PanCancer IO 360 panel to explore predictive signatures for MacroGenics' MGD013 clinical applications.
The companies will comarket Ultivue's UltiMapper assays with Leica's Bond Rx research staining platform for research applications.
A case-control GWAS of individuals of African descent led to four chromosome 6 SNPs with apparent ties to bleeding risk associated with warfarin anticoagulants.
The group aims to collect and sequence more than 2,500 blood samples by 2020 to improve primary diagnosis and treatment options for patients suffering from Parkinson's disease.
Using samples from different points in patients' treatment, researchers employed a variety of tools, including NanoString's GeoMx DSP, to explore potential response markers.
The group plans to use the assay for translational studies on metastasis and drug resistance initially and to develop a clinical version later on.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.